In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

“The observed ocular benefits may be attributable to tirzepatide’s superior metabolic effects, along with potential neuroprotective properties mediated by” the drug’s activation of both ...

GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...

Researchers say a woman struggling with obesity who couldn't resist eating fatty foods experienced declines in her cravings after taking tirzepatide, the GLP-1 weight-loss drug used in Mounjaro and ...

Roche’s CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatide—plus what’s next for ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low ...

These drugs work by targeting GLP-1, a satiety hormone that has been sh… ...